• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

    135.14 -0.29 (-0.21%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 13, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Jazz Pharmaceuticals plc - Ordinary Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    14 15 Next >
    Zymeworks Offers Hope for More than Just Long-Term Investors
    Zymeworks stock is up nearly 5% since reporting earnings and a rally that has put ZYME stock over 25% in the last 12 months and could send the stock higher 
    Via MarketBeat
    With Access To $20 Million In Financing, 1606 Corp Is Eyeing CBD Business Acquisitions As It Embarks On An Aggressive Growth Path
    The global CBD market is on an upward trajectory, and there are no indications that the growth could be slowing down anytime soon. The market was valued at $5.18 billion in 2021 and is expected to... 
    Via Benzinga
    Pharma Mafia Wants To Conquer Cannabis: Can You Patent A Plant? Jazz Is Trying
    The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) recently published collected data on CBD safety, placing the information under its Yellow Card alert system, which lists various... 
    Via Benzinga
    The Latest Analyst Ratings for Jazz Pharmaceuticals
     
    Via Benzinga
    Why Cannabis Is Recession-Resistant & Turning Challenges Into Opportunities, Industry Expert Explains
    It is safe to say that the cannabis industry would not have progressed as much as it has if it were not for the people who believed in it. Cannabis advocates, lobbyists, growers, operators, consumers... 
    Via Benzinga
    Earnings Scheduled For March 1, 2023
    Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
    Via Benzinga
    Earnings Preview For Jazz Pharmaceuticals
     
    Via Benzinga
    Will Investors Notice Exciting Sign On Jazz Pharmaceuticals's Chart?
     
    Via Benzinga
    Jazz Q4 2022 Revenue Grows 8% To $972M, Provides Outlook
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Q4 2022 revenue was $972.12 million an 8% increase compared to 896.73 million in Q4 2021. Financial Highlights 
    Via Benzinga
    Cannabis-Based Medicine As A Potential Treatment For Psychosis, An Oxford University Study Says
    The Department of Psychiatry at the University of Oxford will conduct an international study to investigate whether cannabis-based medicine can treat psychosis. 
    Via Benzinga
    Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling
    The company only just gained approval for its depression drug in August. 
    Via Investor's Business Daily
    GlycoMimetics Audio Discussion And Analysis With Dan Cohen And Scott Matusow
    Dan Cohen and Scott Matusow discuss In this 1:11 audio the upcoming data sets for Glycomimetics. We talk about The Company's platform chemistry in depth, and give our predictions for success/failure of... 
    Via Talk Markets
    2 Cannabis Stocks That Could Make You Richer
    These two stocks could grow like weeds in the next five years and beyond. 
    Via The Motley Fool
    CBD-Based Life-Changing Drug For Tuberous Sclerosis Patients, Epidiolex, Now Available Via England's NHS
    The National Health Service England confirmed Tuesday that starting this week, doctors can prescribe Jazz Pharmaceuticals (NASDAQ: JAZZ) Epidiolex, a CBD-based medicine, to patients suffering from... 
    Via Benzinga
    2 Cannabis Stocks to Buy for the Long Haul
    Don't give up on this sector too quickly. 
    Via The Motley Fool
    Jazz Pharma Opts In, Advances Zanidatamab Partnership With Zymeworks
     
    Via Benzinga
    3 Cannabis Stocks With Double-Digit Percentage Revenue Growth
    Their shares may be down, but their sales are up. 
    Via The Motley Fool
    The Ultimate Growth Stocks to Buy With $300 Right Now
    These three companies should deliver inflation-busting long-term growth. 
    Via The Motley Fool
    2 Promising New Growth Stocks to Watch in 2023
    These stocks have plenty of room to run. 
    Via The Motley Fool
    Jazz Pharma, Zymeworks Highlight 84% Overall Survival At 18 Months From Zanidatamab In Esophageal Cancer
     
    Via Benzinga
    2 Stocks That Beat the Market in 2022 and That Analysts Think Can Go Higher
    There are still plenty of growth opportunities left for these businesses. 
    Via The Motley Fool
    These Stocks Jumped 100% and 30% Last Year. Here's Why They're Still a Buy.
    These stocks look cheap if you take a long-term view. 
    Via The Motley Fool
    6 Analysts Have This to Say About Jazz Pharmaceuticals
     
    Via Benzinga
    Jazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey's District Court
    Jazz Pharmaceuticals (NASDAQ: JAZZ), a drug company behind the CBD-based medication Epidiolex, recently filed a lawsuit against Teva Pharmaceutical Industries Ltd (NYS 
    Via Benzinga
    2 Growth Stocks to Buy Heading Into 2023
    These biotechs are far from having achieved their full potential. 
    Via The Motley Fool
    2 Top Biotech Stocks to Buy for the Long Haul
    These mid-cap biotechs are solid long-term choices. 
    Via The Motley Fool
    Better Buy: Moderna vs Axsome
    Revenue prospects look promising for both of these biotech companies. 
    Via The Motley Fool
    Tesla, Amazon, Micron, Sintx, Zymeworks: Why These 5 Stocks Are Drawing Investors' Attention Today
    U.S. markets soared on Wednesday as consumer confidence surged to an eight-month high in December following a drop in inflation and the labor market remaining strong. Twelve-month inflation... 
    Via Benzinga
    After Jumping 100%, Is Axsome a Buy Before 2023?
    Axsome's revenue story is just getting started. 
    Via The Motley Fool
    Netflix To Rally Around 29%? Here Are 10 Other Price Target Changes For Friday
    Wells Fargo raised Netflix, Inc. (NASDAQ: NFLX) price target from $300 to $400. Wells Fargo also upgraded the stock from Equal Weight to Overweight. Netflix shares rose 0.6% to close at $310.26 on... 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    14 15 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.